Electrophysiology

Our focus

Grounded in meaningful innovation and clinical research, our electrophysiology portfolio is advancing the diagnosis and treatment of heart rhythm disorders while simplifying cardiac ablation procedures—empowering physicians to improve the quality of life for millions of patients worldwide.

Jeana's story

Innovation at the heart of progress

We are redefining what’s possible for atrial fibrillation (AF) treatment with technologies designed to advance safety, increase operational predictability and improve procedural outcomes.

The cutting edge of ablation.

Advancements in treating atrial arrhythmias have expanded therapeutic options for physicians, including the FARAPULSE™ Pulsed Field Ablation (PFA) Platform – a non-thermal method for cardiac ablation designed to safely, precisely and predictably ablate cardiac tissue, while preserving adjacent tissue. This integrated platform combines mapping, access and ablation technologies to support confident workflows and optimal patient outcomes.

A visionary approach to PFA.

The OPAL HDx™ Mapping System provides an integrated environment for navigation and mapping across FARAPULSE PFA Platform and radiofrequency (RF) procedures. Complemented by a single-catheter solution for mapping and ablating, the system empowers physicians to plan, execute and confirm complex ablations with confidence. Further, as our technologies continuously advance, OPAL HDx is evolving toward integrating advanced diagnostic mapping to support the identification of non-pulmonary vein sources of AF and change how physicians visualize and understand its mechanisms.

Access better outcomes.

Our transseptal crossing platforms facilitate predictable and safe left heart access by using RF energy – a method shown to increase efficiency and improve the safety and efficacy of transseptal puncture during left heart procedures. The VersaCross™ RF Transseptal Solution streamlines these crossing procedures and therapy delivery by reducing wire and sheath exchanges, while the VersaCross Connect™ Platform enables an integrated, zero-exchange left heart access workflow compatible with FARADRIVE™ and WATCHMAN™ sheaths, which may help mitigate risks during procedures.

FARAPULSE PFA Platform: More than 500,000 patients treated, clinically and commercially.

FARAPULSE PFA Platform: More than 80% of people treated showed no recurrence of AFib symptoms one-year post-procedure¹ ^†

OPAL HDx^TM Mapping System: Provides integrated mapping for both RF and PFA procedures

≈80%

An estimated 80% of all AF ablation procedures are expected to use PFA by 2028.²

≈900K

An estimated 900K electrophysiology ablation procedures were performed in the U.S. in 2024.²

1.2M

More than 1.2M transseptal procedures are performed globally every year.³

Conditions we treat

Cardiac Arrhythmias

Solutions we offer

Pulsed field ablation
Radiofrequency ablation
Left heart access systems
Mapping and navigation equipment

Product spotlights

FARAPULSE PFA Platform

The FARAPULSE PFA Platform is comprised of devices that support a full workflow – from transseptal access to leading PFA technology with integrated mapping capabilities. The ablation system is optimized for patient safety, predictability and procedural ease. The most clinically studied PFA platform, it addresses many risks associated with traditional thermal cardiac ablation and enables physicians to predictably ablate cardiac tissue while minimizing procedural complications, such as impact to surrounding structures.^4,5

FARAVIEW™ Software on the OPAL HDxTM Mapping System

FARAVIEW^TM Software on the OPAL HDx^TM Mapping System

The FARAVIEW Software Module, seamlessly integrated with the OPAL HDx Mapping System, provides a single-catheter solution for mapping and ablating via the navigation-enabled FARAPULSE PFA Platform catheters. This integrated solution delivers dynamic visualization that allows operators to plan, execute, and confirm workflows, further supporting efficient PFA procedures.

VersaCross Connect RF Transseptal Platform

Designed for FARAPULSE PFA Platform and WATCHMAN™ LAAC procedures, the proprietary puncture technology of the VersaCross Connect RF Transseptal Platform enables safe and reliable left heart access to deliver critical cardiac therapies. By using RF energy instead of conventional mechanical needles, left heart access is more predictable, with reduced rates of serious complications. The platform reimagines left heart access by reducing device exchanges during a procedure, while still using standard-of-care RF puncture technology.

Sources

Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023 May 18;148(1):35–46.
Internal Boston Scientific analysis, Market research
Medtech 360 – Electrophysiology Mapping and Ablation Devices – Market Insights, internal data on file
Reddy VY, Neuzil P, Koruth JS, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74(3):315-326. doi:10.1016/j.jacc.2019.04.021
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444. doi:10.1016/j.hrthm.2017.05.012

^†In a clinical trial 81.6% of people with paroxysmal AFib had no atrial fibrillation, atrial flutter or atrial tachycardia after a single ablation procedure at 12 months.

My account